# **MATTERS ARISING**

**Open Access** 

# Comment on human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis

Hongyu Wang<sup>1\*†</sup> and Lin Zhong<sup>2†</sup>

Dear Editor

We read the article by Unterberg et al. published in Critical Care with great interest [1]. The authors found that several biomarkers, such as procalcitonin, IL-10, and IL-6, could predict outcomes only in HCMV-seropositive patients. However, we wish to draw attention to some key aspects that might have been overlooked in the study.

First, the proportion of HCMV reactivation patients found in this study is much lower compared to previous studies [2–5]. The previous studies in this field included immunocompetent patients, whereas this study incorporated a significant number of immunocompromised patients. Why, in this case, does this research show a lower rate of HCMV reactivation compared to what has been reported in previous studies? We inquire whether some patients in this study received CMV prophylactic treatment, as is routine in posttransplant cases, which may reduce the reactivation of CMV. Meanwhile, drug treatments such as rituximab and bortezomib may deplete B cells, thereby reducing the significance of HCMV seropositivity.

<sup>†</sup>Hongyu Wang and Lin Zhong have been contributed equally.

This comment refers to the article available online at https://doi.org/10.1186/ s13054-023-04713-1.

\*Correspondence:

Hongyu Wang

hongyu260@163.com

<sup>1</sup> The Fifth Clinical Medical College of Henan University of Chinese Medicine Zhengzhou, China

<sup>2</sup> The First People's Hospital of Pinghu, Pinghu, China

The first reopies hospital of filight, filight, china

Second, the absence of HCMV reactivation in early deceased patients raises the necessity of factoring in early mortality as a competing variable when calculating the incidence of HCMV reactivation. Third, existing research has demonstrated that secondary infections might significantly impact the mortality of HCMV patients [2]. Consequently, incorporating data on secondary infections would yield more accurate and comprehensive insights. The better predictive power of IL-6 and PCT in patients at high risk of secondary infection might be one of the reasons. Finally, simultaneous reactivation of various herpesviruses has been identified in various studies [4, 5]. Thus, we recommend further investigations into the concurrent reactivation of diverse herpesviruses for future research.

In conclusion, while this study holds significant implications for the investigation of biomarkers in HCMV-seropositive patients, there is a need for further refinement, including preventive treatment measures, and the impact of other concurrent herpesviruses. These additional studies will contribute to a more comprehensive understanding of the clinical implications related to HCMV reactivation.

HW and LZ participated in the discussion and wrote the manuscript.

Funding None.

Availability of data and materials None.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Author contributions

## Declarations

**Ethics approval and consent to participate** None.

### **Competing interests**

None.

Received: 6 November 2023 Accepted: 9 November 2023 Published online: 17 November 2023

### References

- 1. Unterberg M, Ehrentraut SF, Bracht T, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis. Crit Care. 2023;27(1):417.
- Gatto I, Biagioni E, Coloretti I, et al. Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. Intensive Care Med. 2022;48(6):706–13.
- Ong DSY, Spitoni C, Klein Klouwenberg PMC, et al. Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome. Intensive Care Med. 2016;42(3):333–41.
- Xu J, Zhong L, Shao H, et al. Incidence and clinical features of HHV-7 detection in lower respiratory tract in patients with severe pneumonia: a multicenter, retrospective study. Crit Care. 2023;27(1):248.
- 5. Huang L, Zhang X, Pang L, et al. Viral reactivation in the lungs of patients with severe pneumonia is associated with increased mortality, a multi-center, retrospective study. J Med Virol. 2023;95(1):e28337.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.